CELLNOVO |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | -.--% |
| 2019 | Cellnovo Group Stops Manufacturing and Commercial Operations | CI |
| 2019 | Cellnovo Group Sa Provides Revenue Guidance for the First Quarter of 2019 | CI |
| Sales 2018 | 2.57M 2.74M | Sales 2019 * | - | Capitalization | 2.44M 2.59M |
|---|---|---|---|---|---|
| Net income 2018 * | -15M -15.98M | Net income 2019 * | - | EV / Sales 2018 | 8.63 x |
| Net Debt 2018 * | 9.6M 10.22M | Net cash position 2019 * | - 0 | EV / Sales 2019 * | - |
| P/E ratio 2018 * |
-0.13
x | P/E ratio 2019 * |
-
| Employees | - |
| Yield 2018 * |
-
| Yield 2019 * |
-
| Free-Float | 99.67% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Sophie Baratte
CEO | Chief Executive Officer | 61 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sophie Baratte
CEO | Chief Executive Officer | 61 | 13-12-31 |
Cellnovo Group SA is a France-based company principally engaged in medical instrument manufacturing . The Company specialized in the development of a mobile system for managing type 1 diabetes. Its apparatus includes a cordless micro-pump (a patch pump), an integrated monitoring device and a cellular handset with touch screen with an embedded blood glucose meter. The Company system enables diabetics to live a normal life whilst closely monitoring their glycaemia, their use of insulin, their activity and their food intake.
Sector
Software
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 2.68M | |
| +11.90% | 22.56B | |
| -34.08% | 19.2B | |
| -1.02% | 2.46B | |
| -24.49% | 1.86B | |
| +69.71% | 1.75B | |
| -44.09% | 1.71B | |
| -3.27% | 1.32B | |
| -1.22% | 1.24B | |
| -19.73% | 1.23B |
- Stock Market
- Equities
- CLNV Stock
